Comparative effectiveness of opioid replacement agents for neonatal opioid withdrawal syndrome: a systematic review and meta-analysis.
Journal
Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
07
04
2019
accepted:
22
05
2019
pubmed:
19
7
2019
medline:
17
7
2020
entrez:
19
7
2019
Statut:
ppublish
Résumé
To compare short-term treatment outcomes of opioid pharmacotherapy for neonatal opioid withdrawal syndrome (NOWS). PubMed/MEDLINE, Embase, PsycINFO, and The Cochrane Library were searched from inception through September 30, 2018. Primary outcome was treatment duration (LOT). Secondary outcomes included hospitalization duration (LOS) and rate of adjunct drug needed (RAD). Of 753 publications, 11 studies met inclusion criteria. There was no difference in LOT (WMD -1.39 [-5.79 to -3.01] days, I Methadone had superior primary treatment success compared with morphine. Buprenorphine was associated with the shortest overall durations of treatment and hospitalization.
Identifiants
pubmed: 31316147
doi: 10.1038/s41372-019-0437-3
pii: 10.1038/s41372-019-0437-3
pmc: PMC7784556
mid: NIHMS1059952
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine
40D3SCR4GZ
Morphine
76I7G6D29C
Methadone
UC6VBE7V1Z
Types de publication
Comparative Study
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1535-1545Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM008464
Pays : United States
Références
Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med. 2015;372:2118–26.
doi: 10.1056/NEJMsa1500439
Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol: Off J Calif Perinat Assoc. 2015;35:667.
doi: 10.1038/jp.2015.63
Kocherlakota P. Neonatal abstinence syndrome. Pediatrics. 2014;134:e547–61.
doi: 10.1542/peds.2013-3524
Osborn DA, Jeffery HE. Cole MJ, Opiate treatment for opiate withdrawal in newborn infants. Cochrane Datab Syst Rev. 2010;10:Cd002059.
Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane Datab Syst Rev. 2010;10:Cd002053.
Hudak ML, Tan RC. Neonatal drug withdrawal. Pediatrics. 2012;129:e540–60.
doi: 10.1542/peds.2011-3212
Bogen DL, Whalen BL, Kair LR, Vining M, King BA. Wide variation found in care of opioid-exposed newborns. Acad Pedia. 2017;17:374–80.
doi: 10.1016/j.acap.2016.10.003
Crocetti MT, Amin DD, Jansson LM. Variability in the evaluation and management of opiate-exposed newborns in Maryland. Clin Pediatr. 2007;46:632–5.
doi: 10.1177/0009922807300699
Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol: Off J Calif Perinat Assoc. 2006;26:15–7.
doi: 10.1038/sj.jp.7211427
Mehta A, Forbes KD, Kuppala VS. Neonatal abstinence syndrome management from prenatal counseling to postdischarge follow-up care: results of a national survey. Hosp Pediatr. 2013;3:317–23.
doi: 10.1542/hpeds.2012-0079
Disher T, Gullickson C, Singh B, Cameron C, Boulos L, Beaubien L, et al. Pharmacological treatments for neonatal abstinence syndrome: a systematic review and network meta-analysis. JAMA Pediatr. 2019;173:234–43.
doi: 10.1001/jamapediatrics.2018.5044
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Method. 2014;14:135.
doi: 10.1186/1471-2288-14-135
Sutter MB. Morphine versus methadone for opiate exposed infants with neonatal abstinence syndrome. NLM identifier: NCT02851303 https://clinicaltrials.gov/ct2/show/NCT02851303?type=Intr&cond=Neonatal+Abstinence+Syndrome&rank=14 .
Martin G. Comparison of buprenorphine to morphine in treatment of neonatal abstinence Syndrome (NAS). NLM identifier: NCT01708707 https://clinicaltrials.gov/ct2/show/NCT01708707?type=Intr&cond=Neonatal+Abstinence+Syndrome&rank=11 .
Kushnir A. Treatment of neonatal abstinence syndrome with clonidine versus morphine as primary therapy. NLM identifier: NCT03092011 https://clinicaltrials.gov/ct2/show/NCT03092011?type=Intr&cond=Neonatal+Abstinence+Syndrome&draw=2&rank=1 .
Gauda E. Sublingual buprenorphine treatment for neonatal abstinence syndrome - Pilot Study. NLM identifier: NCT02249026 https://clinicaltrials.gov/ct2/show/NCT02249026?type=Intr&cond=Neonatal+Abstinence+Syndrome&rank=25 .
Davis JM, Lester B. Improving outcomes in neonatal abstinence syndrome. NLM identifier: NCT01958476 https://clinicaltrials.gov/ct2/show/NCT01958476type=Intr&cond=Neonatal+Abstinence+Syndrome&rank=6 .
Brooks S. Methadone Demonstration Project. NLM identifier: NCT03134703 https://clinicaltrials.gov/ct2/show/NCT03134703?type=Intr&cond=Neonatal+Abstinence+Syndrome&rank=20 .
Bada HS. Non-opiate treatment after prenatal opiate exposure to prevent postnatal injury to the young brain (No-POPPY). NLM identifier: NCT03396588 https://clinicaltrials.gov/ct2/show/NCT03396588?type=Intr&cond=Neonatal+Abstinence+Syndrome&rank=18 .
Hall ES, Rice WR, Folger AT, Wexelblatt SL. Comparison of neonatal abstinence syndrome treatment with sublingual buprenorphine versus conventional opioids. Am J Perinatol. 2018;35:405–12.
doi: 10.1055/s-0037-1608634
Burke S, Beckwith AM. Morphine versus methadone treatment for neonatal withdrawal and impact on early infant development. Glob Pediatr health. 2017;4:2333794x17721128.
pubmed: 28804749
pmcid: 5533256
Brown MS, Hayes MJ, Thornton LM. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol: Off J Calif Perinat Assoc. 2015;35:278–83.
doi: 10.1038/jp.2014.194
Young ME, Hager SJ, Spurlock D Jr. Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome. Am J Health-Syst Pharm: AJHP: Off J Am Soc Health-Syst Pharm. 2015;72(23Suppl 3):S162–7.
doi: 10.2146/sp150025
Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA, et al. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics. 2014;134:e527–34.
doi: 10.1542/peds.2013-4036
Patrick SW, Kaplan HC, Passarella M, Davis MM, Lorch SA. Variation in treatment of neonatal abstinence syndrome in US children’s hospitals, 2004–2011. J Perinatol: Off J Calif Perinat Assoc. 2014;34:867–72.
doi: 10.1038/jp.2014.114
Lainwala S, Brown ER, Weinschenk NP, Blackwell MT, Hagadorn JI. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care: Off J Natl Assoc Neonatal Nurses. 2005;5:265–72.
doi: 10.1016/j.adnc.2005.06.003
Kraft WK, Adeniyi-Jones SC, Chervoneva I, Greenspan JS, Abatemarco D, Kaltenbach K, et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. New Engl J Med. 2017;376:2341–8.
doi: 10.1056/NEJMoa1614835
Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction. 2011;106:574–80.
doi: 10.1111/j.1360-0443.2010.03170.x
Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008;122:e601–7.
doi: 10.1542/peds.2008-0571
Hall ES, Isemann BT, Wexelblatt SL, Meinzen-Derr J, Wiles JR, Harvey S, et al. A cohort comparison of buprenorphine versus methadone treatment for neonatal abstinence syndrome. J Pediatr. 2016;170:39–44.e1.
doi: 10.1016/j.jpeds.2015.11.039
Bada HS, Sithisarn T, Gibson J, Garlitz K, Caldwell R, Capilouto G, et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics. 2015;135:e383–91.
doi: 10.1542/peds.2014-2377
Esmaeili A, Keinhorst AK, Schuster T, Beske F, Schlosser R, Bastanier C. Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. Acta Paediatr. 2010;99:209–14.
pubmed: 19839963
Devlin LA, Lau T, Radmacher PG. Decreasing total medication exposure and length of stay while completing withdrawal for neonatal abstinence syndrome during the neonatal hospital stay. Front Pedia. 2017;5:216.
doi: 10.3389/fped.2017.00216
Surran B, Visintainer P, Chamberlain S, Kopcza K, Shah B, Singh R. Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. J Perinatol: Off J Calif Perinat Assoc. 2013;33:954–9.
doi: 10.1038/jp.2013.95
Coyle MG, Ferguson A, Lagasse L, Liu J, Lester B. Neurobehavioral effects of treatment for opiate withdrawal. Arch Dis Child Fetal neonatal Ed. 2005;90:F73–4.
doi: 10.1136/adc.2003.046276
Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr. 2002;140:561–4.
doi: 10.1067/mpd.2002.123099
Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009;123:e849–56.
doi: 10.1542/peds.2008-0978
Davis JM, Shenberger J, Terrin N, Breeze JL, Hudak M, Wachman EM, et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pedia. 2018;172:741–8.
doi: 10.1001/jamapediatrics.2018.1307
Tolia VN, Murthy K, Bennett MM, Greenberg RG, Benjamin DK, Smith PB, et al. Morphine vs methadone treatment for infants with neonatal abstinence syndrome. J Pediatr. 2018;203:185–9.
doi: 10.1016/j.jpeds.2018.07.061
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–31.
doi: 10.1056/NEJMoa1005359
Kraft WK, Stover MW, Davis JM. Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Semin Perinatol. 2016;40:203–12.
doi: 10.1053/j.semperi.2015.12.007
Boumeester NJ, AB, Tibboel D, et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants, ad young children. Br J Anaesth. 2004;92:208–17.
doi: 10.1093/bja/aeh042
Kraft WK. Buprenorphine in neonatal abstinence syndrome. Clin Pharmacol Ther. 2018;103:112–9.
doi: 10.1002/cpt.930
Blume HK, Garrison MM, Christakis DA. Neonatal seizures: treatment and treatment variability in 31 United States pediatric hospitals. J Child Neurol. 2009;24:148–54.
doi: 10.1177/0883073808321056
Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133–53.
pubmed: 18443637
Corr TE, Hollenbeak CS. The economic burden of neonatal abstinence syndrome in the United States. Addiction. 2017;112:1590–9.
doi: 10.1111/add.13842
MacMillan KDL, Rendon CP, Verma K, Riblet N, Washer DB, Volpe Holmes A. Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pedia. 2018;172:345–51.
doi: 10.1001/jamapediatrics.2017.5195